0001628280-21-019048.txt : 20210922 0001628280-21-019048.hdr.sgml : 20210922 20210922163103 ACCESSION NUMBER: 0001628280-21-019048 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210920 FILED AS OF DATE: 20210922 DATE AS OF CHANGE: 20210922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martin Michael Robert CENTRAL INDEX KEY: 0001837647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 211269996 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA STATE: A1 ZIP: BC V8Z7X8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 4 1 wf-form4_163234265014624.xml FORM 4 X0306 4 2021-09-20 0 0001600620 Aurinia Pharmaceuticals Inc. AUPH 0001837647 Martin Michael Robert #1203-4464 MARKHAM STREET VICTORIA A1 V8Z7X8 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Business Officer Common Stock 2021-09-20 4 M 0 28500 5.30 A 205361 D Common Shares 2021-09-20 4 S 0 12500 21.71 D 192861 D Common Shares 2021-09-20 4 S 0 16000 21.60 D 176861 D Common Stock 2021-09-21 4 M 0 7500 5.30 A 184361 D Common Stock 2021-09-21 4 M 0 70000 6.06 A 254361 D Common Stock 2021-09-21 4 M 0 10000 18.38 A 264361 D Common Shares 2021-09-21 4 S 0 87500 24.02 D 176861 D Option Grant (right to buy) 5.3 2021-09-20 4 M 0 28500 5.30 D 2028-02-01 Common Stock 28500.0 7500 D Option Grant (right to buy) 5.3 2021-09-21 4 M 0 7500 0 D 2028-02-01 Common Stock 7500.0 0 D Option Grant (right to buy) 6.06 2021-09-21 4 M 0 70000 0 D 2029-01-29 Common Stock 70000.0 0 D Option Grant (right to buy) 18.38 2021-09-21 4 M 0 10000 0 D 2030-01-28 Common Stock 10000.0 56900 D Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.70 to $21.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.56 to $21.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.90 to $24.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to the option vest in thirty-six equal monthly installments from the grant date. The shares subject to the option vest in twenty-four equal monthly installments from the grant date. /s/ Michael Robert Martin 2021-09-22